A Phase II, Randomized, Double-blind, Multi-center, Placebo-Controlled Study of the Efficacy and Safety of CEND-1 in Combination With Chemotherapy as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Cerepetide (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 27 Feb 2025 According to a Lisata Therapeutics media release, Qilu has completed enrollment in its Phase 2 trial and data are expected in the coming months.
- 10 May 2024 According to a Lisata Therapeutics media release, Qilu has begun treating patients in their Phase 2 placebo-controlled trial in mPDAC. The study is planned to take approximately 18 months to complete enrollment and another 13 months for patient follow-up and data analysis and reporting.
- 23 Apr 2024 According to a Lisata Therapeutics media release, the first patient has been treated in Phase 2 trial in China evaluating LSTA1 as a first-line treatment for metastatic pancreatic ductal adenocarcinoma .